Zenotech Laboratories (BOM:532039) ROCE % : 5.92% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zenotech Laboratories's annualized ROCE % for the quarter that ended in Mar. 2024 was 5.92%.

Zenotech Laboratories ROCE % Historical Data

The historical data trend for Zenotech Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenotech Laboratories ROCE % Chart

Zenotech Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

26.12

0.55

14.88

17.96

12.59

Zenotech Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															16.53	9.81	17.61	17.18	5.92

Zenotech Laboratories ROCE % Calculation

Zenotech Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	111.414	/	( ( (1008.73 - 166.07)	+	(1062.064 - 135.231) )	/ 2 )
	=	111.414	/	( (842.66	+	926.833)	/ 2 )
	=	111.414	/	884.7465
	=	12.59 %

Zenotech Laboratories's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	54.9	/	( ( (0 - 0)	+	(1062.064 - 135.231) )	/ 1 )
	=	54.9	/	( ( 0	+	926.833 )	/ 1 )
	=	54.9	/	926.833
	=	5.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Zenotech Laboratories (BOM:532039) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zenotech Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Zenotech Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenotech Laboratories (BOM:532039) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078

Website

http://www.zenotechlab.com

Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories (BOM:532039) Headlines

No Headlines